Promising rectal cancer study



Promising rectal cancer study

A scientist comments on the evolving treatment of rectal cancer in light of findings from a study that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer.

Materials provided by UNC Lineberger Comprehensive Cancer Center. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

31st March 2023

Form is (mal)function: Protein's shape lets bacteria disarm it

Read more
30th March 2023

Researchers discover a way to fight the aging process and cancer development

Read more
30th March 2023

Researchers identify cell type that could be key to preventing marrow transplant complication

Read more